Matches in Nanopublications for { ?s ?p "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP544862.RAYippW09LEEPhwdSxpeg9puo5Hd1U5bGPXFD6GjVYzGA130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP544862.RAYippW09LEEPhwdSxpeg9puo5Hd1U5bGPXFD6GjVYzGA130_provenance.
- assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP951463.RAtKLhLcpNQ395lZd8dnX3VVohUoudwwCB6j5WMMhKYv0130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951463.RAtKLhLcpNQ395lZd8dnX3VVohUoudwwCB6j5WMMhKYv0130_provenance.
- assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1404216.RAVGWxPxlXJ7s_vUL0Ge6ftEOk5Qv9kMtq3AzNJzmUjt4130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404216.RAVGWxPxlXJ7s_vUL0Ge6ftEOk5Qv9kMtq3AzNJzmUjt4130_provenance.
- NP1009689.RArYxxFl7ysOIY8CXwWHKVfIW0ic8uT_BwqahcSU_fcds130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1009689.RArYxxFl7ysOIY8CXwWHKVfIW0ic8uT_BwqahcSU_fcds130_provenance.
- NP1404218.RAkZhV8EyMXJbxQWsqZSs7qC5rUg-scnwoKX6DwqkK3zI130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404218.RAkZhV8EyMXJbxQWsqZSs7qC5rUg-scnwoKX6DwqkK3zI130_provenance.
- NP1404211.RAH-c6psX_24CzSLES0EQLE7wEHllDQRcPpGgQrT2wsPM130_assertion description "[Finally, this study indicates that serous cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404211.RAH-c6psX_24CzSLES0EQLE7wEHllDQRcPpGgQrT2wsPM130_provenance.